Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer (vol 9, e002100, 2021)

被引：0
|
作者：
Wang, H.
Ma, H.
Sove, R. J.
机构：
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷 / 10期
关键词：
D O I：
10.1136/jitc-2020-002100corr1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
    Emens, L.
    Adams, S.
    Loi, S.
    Schmid, P.
    Schneeweiss, A.
    Rugo, H.
    Chui, S.
    Winer, E.
    CANCER RESEARCH, 2016, 76
  • [32] Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).
    Yam, Clinton
    Mittendorf, Elizabeth A.
    Sun, Ryan
    Huo, Lei
    Damodaran, Senthil
    Rauch, Gaiane M.
    Candelaria, Rosalind P.
    Adrada, Beatriz E.
    Seth, Sahil
    Symmans, William Fraser
    Murthy, Rashmi Krishna
    White, Jason B.
    Ravenberg, Elizabeth
    Clayborn, Alyson
    Prabhakaran, Sabitha
    Valero, Vicente
    Thompson, Alastair Mark
    Tripathy, Debu
    Moulder, Stacy L.
    Litton, Jennifer Keating
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
    Chen, Nan
    Saha, Poornima
    Rampurwala, Murtuza M.
    Kamaraju, Sailaja
    Hahn, Olwen Mary
    Howard, Frederick Matthew
    Fleming, Gini F.
    Matossian, Margarite
    Freeman, Jincong Q.
    Karrison, Theodore
    Conzen, Suzanne D.
    Nanda, Rita
    Stringer-Reasor, Erica Michelle
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] A phase II trial of neoadjuvant apatinib combined with nab-paclitaxel and carboplatin in triple-negative breast cancer
    Zeng, Tianyu
    Wang, Jue
    Li, Wei
    Sun, Chunxiao
    Yang, Fan
    Liang, Yan
    Fu, Ziyi
    Zha, Xiaoming
    Yin, Yongmei
    ANNALS OF ONCOLOGY, 2022, 33 : S492 - S492
  • [35] A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
    Chen, Nan
    Matossian, Margarite
    Saha, Poornima
    Rampurwala, Murtuza
    Kamaraju, Salaija
    Hahn, Olwen
    Howard, Frederick M.
    Fleming, Gini F.
    Freeman, Jincong Q.
    Karrison, Theodore
    Conzen, Suzanne
    Nanda, Rita
    Stringer-Reasor, Erica M.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 111 - 119
  • [36] ANTITUMOR ACTIVITY OF NAB-PACLITAXEL AND BEVACIZUMAB AGAINST A NEW TRIPLE NEGATIVE BREAST CANCER MODEL
    Trieu, V.
    Blackwell, K. L.
    Volk, L.
    Wilber, A.
    Desai, N.
    ANNALS OF ONCOLOGY, 2010, 21 : 43 - 43
  • [37] Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan
    Chisaki, Yugo
    Kuwada, Yoshiki
    Matsumura, Chikako
    Yano, Yoshitaka
    CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 381 - 389
  • [38] Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan
    Yugo Chisaki
    Yoshiki Kuwada
    Chikako Matsumura
    Yoshitaka Yano
    Clinical Drug Investigation, 2021, 41 : 381 - 389
  • [39] The tumor microenvironment (TME) and atezolizumab plus nab-paclitaxel (A plus nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.
    Emens, Leisha A.
    Goldstein, Leonard D.
    Schmid, Peter
    Rugo, Hope S.
    Adams, Sylvia
    Barrios, Carlos H.
    Schneeweiss, Andreas
    Dieras, Veronique
    Iwata, Hiroji
    Chang, Ching-Wei
    Koeppen, Hartmut
    Chui, Stephen Y.
    Loi, Sherene
    Molinero, Luciana
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Subgroup analysis of IMpassion130: Atezolizumab plus nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries
    Iwata, H.
    Im, S-A.
    Sohn, J.
    Jung, K. H.
    Im, Y-H.
    Lee, K. S.
    Inoue, K.
    Tamura, K.
    Wong, A.
    Emens, L. A.
    Barrios, C. H.
    Adams, S.
    Schneeweiss, A.
    Dieras, V.
    Winer, E. P.
    Chui, S. Y.
    Henschel, V.
    Rugo, H. S.
    Loi, S.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2019, 30
12345